C07K 2319/74
Containing a fusion for binding to a cell surface receptor
Official title: containing a fusion for binding to a cell surface receptor
C07K2319/74 (Containing a fusion for binding to a cell surface receptor) appears on 1,627 US grants and 1,941 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,627
- Published applications
- 1,941
- Assignees
- 902
- Inventors
- 3,422
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 5 | 0 |
| 1987 | 11 | 0 |
| 1988 | 15 | 0 |
| 1989 | 17 | 0 |
| 1990 | 11 | 0 |
| 1991 | 23 | 0 |
| 1992 | 28 | 0 |
| 1993 | 32 | 0 |
| 1994 | 29 | 0 |
| 1995 | 29 | 0 |
| 1996 | 31 | 0 |
| 1997 | 52 | 0 |
| 1998 | 51 | 0 |
| 1999 | 40 | 0 |
| 2000 | 37 | 0 |
| 2001 | 34 | 5 |
| 2002 | 32 | 35 |
| 2003 | 26 | 50 |
| 2004 | 14 | 33 |
| 2005 | 17 | 35 |
| 2006 | 21 | 31 |
| 2007 | 18 | 23 |
| 2008 | 18 | 34 |
| 2009 | 23 | 46 |
| 2010 | 21 | 34 |
| 2011 | 27 | 51 |
| 2012 | 25 | 42 |
| 2013 | 37 | 55 |
| 2014 | 30 | 65 |
| 2015 | 47 | 72 |
| 2016 | 56 | 125 |
| 2017 | 59 | 134 |
| 2018 | 82 | 177 |
| 2019 | 99 | 122 |
| 2020 | 117 | 136 |
| 2021 | 82 | 119 |
| 2022 | 90 | 134 |
| 2023 | 57 | 108 |
| 2024 | 67 | 120 |
| 2025 | 78 | 103 |
| 2026 | 33 | 52 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Targeting of human interferon antagonists22 Sep 2026US 12,741,998 B2Centre Hospitalier Regional Universitaire De Montpellier
- TNFR2 agonists with improved stability15 Sep 2026US 12,735,472 B2Universität Stuttgart
- Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FCγR-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FCγR-independent agonistic activity; TRAAFFIAA)25 Aug 2026US 12,715,928 B2Julius-Maximilians-UniversitäT WüRzburg
- Chimeric antigen receptor (CAR) comprising a CD19-binding domain28 Jul 2026US 12,692,313 B2Autolus Limited
- Methods for engineering allogeneic and highly active T cell for immunotheraphy14 Jul 2026US 12,680,076 B2Cellectis
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Chimeric antigen receptor (car) comprising a cd19-binding domain17 Sep 2026US 2026/0274946 A1Autolus Limited
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Nanostructured proteins and uses thereof10 Sep 2026US 2026/0265317 A1
- Conjugates for Targeted Cell Surface Editing3 Sep 2026US 2026/0258150 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants660US 5,750,373 AGenentech, Inc. · 1998
- Monovalent phage display562US 5,821,047 AGenentech, Inc. · 1998
- Production of vascular endothelial cell growth factor406US 5,194,596 ACalifornia Biotechnology Inc. · 1993
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Expression using fused genes providing for protein product297US 4,751,180 AChiron Corporation · 1988